Avant Technologies Enters Material Definitive Agreement
Ticker: AVAI · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1740797
| Field | Detail |
|---|---|
| Company | Avant Technologies Inc. (AVAI) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, exhibits, company-name-change
Related Tickers: AVAI
TL;DR
AVAI signed a big deal, filing shows financials.
AI Summary
On September 15, 2025, AVANT TECHNOLOGIES INC. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company was formerly known as TREND INNOVATIONS HOLDING INC. and FREECOOK.
Why It Matters
This filing indicates a significant new agreement for Avant Technologies, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The filing reports a material definitive agreement, which introduces potential risks and opportunities that are not yet fully detailed.
Key Players & Entities
- AVANT TECHNOLOGIES INC. (company) — Registrant
- TREND INNOVATIONS HOLDING INC. (company) — Former company name
- FREECOOK (company) — Former company name
- September 15, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by AVANT TECHNOLOGIES INC.?
The filing states that AVANT TECHNOLOGIES INC. entered into a material definitive agreement on September 15, 2025, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 15, 2025.
What were AVANT TECHNOLOGIES INC.'s previous names?
AVANT TECHNOLOGIES INC. was formerly known as TREND INNOVATIONS HOLDING INC. and FREECOOK.
What is the principal executive office address for AVANT TECHNOLOGIES INC.?
The principal executive offices are located at 5348 Vegas Drive, Las Vegas, NV 89108.
What is the SIC code for AVANT TECHNOLOGIES INC.?
The Standard Industrial Classification (SIC) code for AVANT TECHNOLOGIES INC. is 7374, which falls under SERVICES-COMPUTER PROCESSING & DATA PREPARATION.
Filing Stats: 826 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2025-09-18 07:10:31
Key Financial Figures
- $1.5 million — ext eighteen (18) months, not to exceed $1.5 million USD in capital and its resources in exc
Filing Documents
- form8_avai.htm (8-K) — 26KB
- exhibit10_1.htm (EX-10.1) — 133KB
- 0001740797-25-000047.txt ( ) — 344KB
- avai-20250915.xsd (EX-101.SCH) — 3KB
- avai-20250915_lab.xml (EX-101.LAB) — 33KB
- avai-20250915_pre.xml (EX-101.PRE) — 22KB
- form8_avai_htm.xml (XML) — 3KB
01 - Entry into a Material Definitive
Item 1.01 - Entry into a Material Definitive Agreement On September 15, 2025 (the "Effective Date"), Avant Technologies Inc. (the "Company" and "AVAI") entered into a Joint Venture and License Agreement with SGAustria Pte. Ltd., a Singaporean company with registered number UEN 200901830C (the "Austrianova"), collectively referred to as the "Counterparties", setting forth the principal terms of a Joint Venture and License Agreement (the "Agreement"). The Agreement sets forth the understanding of the Counterparties with respect to the formation of a new company, Klothonova Inc. (the "Klothonova"), and contribute the proprietary rights, know-how, resources and funding as described in the License Agreement. Austrianova is a cutting-edge Biotech company based in Singapore embracing leading world quality standards to produce cell-based products. Austrianova's expertise and technologies are backed up by more than 50 international peer reviewed publications, as well as by contracts from leading pharmaceutical and biotech companies. Austrianova's scientists are experts in cell biology, GMP-grade cell products and encapsulation of living cells. Austrianova has developed a proprietary cell encapsulation technology to protect, isolate, store, and transport living cells, as well as oXering cell line development and GMP Manufacturing capabilities and expertise and it intends to contribute its intellectual property, know- how, and resources to Klothonova to achieve the purposes of the Agreement. AVAI will contribute all of the resources and capital required by Klothonova, Inc's formation and operation for the next eighteen (18) months, not to exceed $1.5 million USD in capital and its resources in exchange for the common stock of Klothonova. AVAI will use its best efforts to assist in arranging additional funding as needed, as described in the Agreement, at no cost to Austrianova. The ownership of Klothonova shall be 50% AVAI and 50% Austrianova. The Klothonova will be gover
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking are based on current expectations and assumptions and involve risks and uncertainties. Actual results may differ materially from those described in the forward-looking statements. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Joint Venture and License Agreement dated September 15, 2025
SIGNATURES
SIGNATURES In accordance with the requirements of the Securities Act of 1933, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 18, 2025 AVANT TECHNOLOGIES INC. By: /s/ Vitalis Racius Name: Vitalis Racius Title: Chief Financial Officer, Director & Treasurer